Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial.
D. Malka
Honoraria - Amgen
Research Funding - Amgen
S. Gourgou-Bourgade
No relevant relationships to disclose
J. Emile
No relevant relationships to disclose
P. Laurent-Puig
Honoraria - Amgen
J. Taïeb
Honoraria - Amgen
Research Funding - Amgen